Navigation Links
Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today

NEW ORLEANS and LOS ANGELES, November 10 /PRNewswire/ --

- Current Treatment Fails to Abolish Majority of Vascular Risk

- Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Patients With Heart Disease and Diabetes

Internationally recognized specialists from North America, Europe, Asia and Japan have come together today to launch the Residual Risk Reduction initiative (R3i) - a unique global program to evaluate and reduce the excess risk of myocardial infarction, stroke, kidney disease, loss of vision and non-traumatic limb amputation which exists in many patients with heart disease and diabetes despite optimal, currently available care.

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and microvascular complications in patients with atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care. This lipid abnormality is typical in patients with type 2 diabetes or metabolic syndrome and common in patients with established cardiovascular disease.

The President of the R3i, Professor Jean-Charles Fruchart of the University of Lille, France said: "We now have unequivocal evidence from numerous studies showing that greater reductions in low-density lipoprotein cholesterol, blood pressure and blood sugar alone will have little, if any, additional impact on residual vascular risk. Therefore, we urgently need new strategies to address other modifiable risk factors such as atherogenic dyslipidemia, a strong contributor to residual vascular risk in millions of patients with diabetes and cardiovascular disease."

The R3i will address this major public health problem. In its manifesto published today in Diabetes & Vascular Disease Research (Diabetes Vasc Dis Res 2008;5:319-35) and in a supplement to the American Journal of Cardiology (Am J Cardiol 2008:102:Supplement 10A ), the R3i calls for:

- Original research to quantify the full extent of residual

vascular risk in patients with atherogenic dyslipidemia and to identify

new targets for interventions.

- Educational programs to create awareness of residual vascular

risk and to encourage healthcare professionals, particularly Primary

Care Physicians (PCPs), to translate available research findings into

improved treatment strategies.

- Advocacy to ensure that the issue of residual vascular risk

associated with atherogenic dyslipidemia is given appropriate priority

in national and international guidelines.

"Our overall goal must be to provide knowledge and understanding to allow physicians to get closer to normalizing residual vascular risk in patients with heart disease and/or diabetes," Frank Sacks, Professor of Cardiovascular Disease Prevention, Harvard School of Public Health, Professor of Medicine, Harvard Medical School, Boston, USA and Vice-president of R3i, said. "We hope that the original research conducted under the auspices of R3i and the widespread communication of current knowledge and new data will lead to significant improvements in the reduction of risk beyond the levels we achieve now. Despite significant advances in reducing vascular risk in the last 20 years, we have only just begun to address this issue. We invite our colleagues to join us in addressing this important challenge."

The R3i is led by a Board of Trustees and an International Steering Committee (ISC) of 21 officers and members from the disciplines of cardiology, diabetology, lipidology, endocrinology, epidemiology, nutrition, ophthalmology, nephrology and basic science. The legal body of the R3i will be a Foundation established in Switzerland. National organizations have been or are in the process of being established in more than 40 countries worldwide. These beneficiaries of the R3i Foundation will implement research and educational programs in their respective countries and will also initiate their own national initiatives, according to the mission of the R3i.

The R3i Foundation will seek funding from multiple sources. Initial seed funding was provided by Solvay Pharmaceuticals.

Initial research and education programs focus on extent of residual vascular risk

The initial R3i research program involves two worldwide epidemiological surveys which aim to quantify the full extent of residual macro- and microvascular risk associated with atherogenic dyslipidemia in patients with heart disease and/or type 2 diabetes receiving current standards of care.

Additionally, this research will generate hypotheses about the role of lipid abnormalities such as atherogenicity of serum triglycerides and atheroprotection of high density lipoprotein cholesterol (HDL-C) in the future management of residual vascular risk.

The R3i in its commitment to education has already begun to develop educational tool kits including a resource slide kit and a dedicated website including a CME-accredited program. This will facilitate live web seminars (webinars) allowing physicians to interact and communicate with each other across the globe.

For Notes to Editors, details of the Board of Trustees and the International Steering Committee, countries where R3i national organizations have been or are in the process of being established and references please go to the R3i website:

The website contains information on the members, the mission, the research and the education programs. It also features links to various resources discussing residual vascular risk.

SOURCE Residual Risk Reduction Initiative (R3i)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nanoscience Instruments, Inc. Announces Distribution of Nascatec's Complete Line of Unique AFM Probes and Sensors
2. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
3. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
4. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
5. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
6. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
7. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
8. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
9. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
10. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
11. Unique infrared technique finds applications in nanoscience
Post Your Comments:
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... ... 24, 2015 , ... In harsh industrial processes, the safety ... sensors can represent a weak spot where leaking process media is a possible ... housings , which are designed to tolerate extreme process conditions. They combine rugged ...
(Date:11/24/2015)... Nov. 24, 2015 HemoShear Therapeutics, LLC, ... drugs for metabolic disorders, announced today the appointment ... Board of Directors (BOD). Mr. Watkins is the ... Genome Sciences (HGS), and also served as the ... Jim Powers , Chairman and CEO of HemoShear ...
(Date:11/23/2015)... Women with a certain type of lung nodule visible on ... lung cancer than men with similar nodules, according to a ... of the Radiological Society of North America ... Lung nodules are small masses of tissue in the ... their appearance on CT. Solid nodules are dense, and they ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
Breaking Biology News(10 mins):